Triamcinolone Hexacetonide

Summary

Triamcinolone Hexacetonide (CHEMBL1200878) is an approved small molecule; indicated across 5 conditions including osteoarthritis and rheumatoid arthritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 15
• Chemistry: 532.6 Da · C30H41FO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200878
Name	Triamcinolone Hexacetonide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	21826
Molecular formula	C30H41FO7
Molecular weight	532.6
InChIKey	TZIZWYVVGLXXFV-FLRHRWPCSA-N

SMILES: C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COC(=O)CC(C)(C)C)CCC5=CC(=O)C=C[C@@]53C)F)O

IUPAC name: [2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 3,3-dimethylbutanoate

Also known as: Aristospan, CL 34433, CL-34433, Hexacetonide de triamcinolone, Hexacetonido de triamcinolona, Lederspan, TATBA, Triamcinolone hexacetonide, TRIAMCINOLONE HEXACETONIDE, SID144206532

Patent coverage: 1,999 distinct patent families (8,025 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis	4	MONDO:0005178	MONDO:0005178
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
arthropathy	2	MONDO:0006816	EFO:1000999

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE4	6
Not specified	6
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05306548	PHASE4	ACTIVE_NOT_RECRUITING	A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome
NCT02437461	PHASE4	UNKNOWN	Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis
NCT02829281	PHASE4	UNKNOWN	Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis
NCT03086759	PHASE4	COMPLETED	Intra-Articular Platelet Rich Plasm Use in Osteoarthritis of Knee.
NCT04614311	PHASE4	COMPLETED	Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).
NCT06308887	PHASE4	COMPLETED	Comparison of Ultrasound-Guided Perimeniscal Steroid and 5% Dextrose Injections in Knee Osteoarthritis
NCT03191903	PHASE3	COMPLETED	Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide
NCT03390036	PHASE3	COMPLETED	Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up
NCT01770912	PHASE2	COMPLETED	Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management
NCT05408065	Not specified	RECRUITING	Comparison of the Analgesic Effect of 2 Shoulder Infiltrations
NCT00588354	Not specified	TERMINATED	Epidural Clonidine for Lumbosacral Radiculopathy
NCT00840229	Not specified	COMPLETED	Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder
NCT01026909	Not specified	TERMINATED	Intraarticular Corticosteroid Therapy in Perthes Disease.
NCT01851278	Not specified	UNKNOWN	Effectiveness Intraarticular Corticosteroid
NCT04824612	Not specified	COMPLETED	Photobiomodulation and the Intralesional Administration of Corticoid in the Keloid Surgery.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).